Richard Prins
About Richard Prins
Richard Prins (age 68) is the independent Chairman of IGC’s Board, serving since May 2007; his current Class B term runs through the 2027 annual meeting . He chairs the Audit and Compensation Committees (since 2012) and also serves as Chair of the Board’s Disclosure Committee; the Board designates him (and fellow member James Moran) as an audit committee financial expert under SEC rules . Prins’ background spans investment banking (Director of Investment Banking at Ferris, Baker Watts, 1996–2008; consulting at RBC until Jan 2009), and he holds a B.A. from Colgate University and an M.B.A. from Oral Roberts University .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Ferris, Baker Watts (FBW) | Director of Investment Banking | Mar 1996–2008 | Led investment banking; capital markets expertise |
| RBC | Consultant | 2008–Jan 2009 | Advisory role post-FBW |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Amphastar Pharmaceuticals, Inc. | Director | Since Feb 2003 | Longstanding public biopharma directorship |
Board Governance
- Independence and structure: The Board (small-cap listing on NYSE American) deems Prins independent; the Board separates the Chair and CEO roles, with Prins as independent Chair .
- Committee leadership and expertise:
- Audit Committee: Members Richard Prins (Chair) and James Moran; both designated “audit committee financial experts” .
- Compensation Committee: Members Richard Prins and James Moran; Prins serves as Chair per company disclosure of his committee chairmanship since 2012 .
- Disclosure Committee: Prins is the appointed Chair; committee oversees internal controls and public disclosures and meets at least quarterly .
- Nominating/Governance: Not yet established; company intends to form this committee in the future (current director nominations handled by majority of independent directors) .
- Attendance and engagement:
- FY2025 meetings: Board (6), Audit (5), Compensation (2) – all directors and committee members attended all meetings (implies 100% attendance for Prins) .
- FY2024 meetings: Board (12), Audit (5), Compensation (2), Investment (1) – all attended (implies 100% attendance for Prins) .
| Meeting Activity | FY2024 Count | FY2024 Attendance | FY2025 Count | FY2025 Attendance |
|---|---|---|---|---|
| Board | 12 | All directors attended | 6 | All directors attended |
| Audit Committee | 5 | All members attended | 5 | All members attended |
| Compensation Committee | 2 | All members attended | 2 | All members attended |
Additional policies and governance signals:
- Director stock ownership guidelines require directors to retain 35% of stock received during service (transfers to trusts/gifts excluded) .
- Hedging prohibitions: Officers and non-employee directors are prohibited from hedging company stock (e.g., swaps, collars) .
- Indemnification agreements in place for directors .
Fixed Compensation
- FY2025: “No compensation was awarded to, earned by, or paid to non-employee directors” (i.e., zero director pay in FY2025) .
- The company states it has a “standard compensation arrangement” for non-employee directors (e.g., fees for committee service, chair roles, meeting attendance), but specific cash retainer/fee amounts were not disclosed in FY2024/FY2025 proxies .
Performance Compensation
Director equity compensation (non-employee directors):
- FY2024 director compensation table shows equity-only compensation for Prins (927 stock awards; total grant-date fair value $259k) .
- FY2025: company disclosed no director compensation awards during the fiscal year (i.e., no equity granted) .
- Award types include performance-based (milestone) and market-price-based stock awards per proxy narrative .
| Metric | FY2024 | FY2025 |
|---|---|---|
| Stock awards granted to Prins (count) | 927 | 0 (no director comp awarded) |
| Total equity grant value to Prins ($) | $259,000 | $0 |
Note: Unvested awards at year-end are detailed under Equity Ownership; award categories include performance- and market-price-based grants .
Other Directorships & Interlocks
| Company | Industry | Role | Potential Interlock/Conflict |
|---|---|---|---|
| Amphastar Pharmaceuticals, Inc. | Pharmaceuticals | Director (since 2003) | No related-party transactions between IGC and Prins disclosed; company states no material related-party transactions in last two fiscal years (other than items specifically described) . |
- Related party transactions: Company reports none involving directors in FY2024–FY2025; a March 22, 2024 private placement involved Bradbury Strategic Investment Fund A, not connected to Prins per disclosure .
Expertise & Qualifications
- Capital markets and finance: Former Director of Investment Banking (FBW), with extensive private equity/investment banking experience; strong knowledge of U.S. capital markets .
- Audit expertise: Designated “audit committee financial expert” (with James Moran) under SEC rules; significant experience in finance, accounting, and internal controls .
- Education: B.A. Colgate University; M.B.A. Oral Roberts University .
Equity Ownership
Beneficial ownership and unvested awards:
| Ownership Metric | Jul 1, 2024 (FY2024 reference) | Aug 15, 2025 (FY2025 reference) |
|---|---|---|
| Beneficially owned shares | 1,243,000 (1.64%) | 1,271,251 (1.40%) |
| Unvested stock awards (#) | 1,189 | 936 |
| Unvested stock awards (value) | $653,000 | $540,000 |
- Stock ownership guideline: Directors must retain 35% of stock received while on the Board .
- Hedging policy: Directors are prohibited from hedging company stock .
- Pledging: No pledging disclosures identified in the proxy; not discussed in the cited sections .
Governance Assessment
Key findings:
-
Strengths
- Independent Chair with deep capital markets experience; separation of Chair/CEO supports oversight .
- Prins chairs Audit and Compensation Committees and is designated an audit committee financial expert; committees comprised solely of independent directors .
- Strong engagement: 100% attendance reported for Board and committees in FY2024 and FY2025 .
- Equity alignment: Material personal stake (1.40% of shares), unvested equity, and retention guideline support alignment with shareholders .
-
Watch items / potential red flags
- Nominating/Governance Committee not yet established; director nominations handled by independent directors without a formal committee/charter (common for smaller issuers, but below best practice) .
- Section 16(a) timeliness: late Form 5 filings noted for RSU vesting as of March 31, 2025, including for Richard Prins (administrative compliance lapse) .
- FY2025 disclosed no director compensation (cash or equity). While not inherently a red flag, it is atypical and may indicate grant timing shifts or compensation deferral; investors should watch for clarity in future filings .
-
Conflicts/related-party
- Company reports no related-party transactions involving directors in the last two fiscal years; Bradbury private placement involved no disclosed connection to Prins .
Overall implication:
- Prins’ long-tenured, independent leadership, committee chair roles, and audit expertise are positives for board effectiveness and control oversight. The absence of a formal nominating/governance committee and the late Section 16(a) Form 5 filing are governance gaps to monitor, though not indicative of material conflicts; equity ownership and retention policies support shareholder alignment .